Linda Yingqi Lin

This study shows that gene editing of HSCs without ex vivo culture reduces genotoxicity while maintaining therapeutic efficacy for beta-hemoglobinopathy treatment.

The paper develops ABSOLVE-seq to assess genome editing off-targets linked to genetic variants using primary cells and sequencing, enabling evaluation of human genetic diversity's impact on gene editing specificity.

The paper develops CRISPRme, a tool that integrates genetic diversity data to assess off-target risks of gene editing, finding allele-specific off-target effects in clinical gRNAs.